Clinical Trial Update: Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial investigating primary prophylaxis with rhTPO in high-risk sarcoma patients undergoing intensive chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• rhTPO (recombinant human thrombopoietin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Sarcoma | Phase 3 | Status: COMPLETED